NASDAQ:CNTB
Connect Biopharma Holdings Ltd American Stock News
$1.52
-0.0500 (-3.18%)
At Close: May 07, 2024
Development program exploring the potential of CBP-174 in the treatment of chronic inflammatory pruritus
Week In Review: Genscript And Its Legend Bio Subsidiary Raise $1 Billion From Hillhouse
02:52pm, Sunday, 16'th May 2021
Genscript raised more than $1 billion from Hillhouse Capital in several different investments, including a $500 million commitment to Genscript's Legend Biotech CAR-T subsidiary. Shanghai Fosun Pharma
Connect Biopharma Completes Enrollment of CBP-201 Global Phase 2 Clinical Trial in Moderate-to-Severe Atopic Dermatitis
08:00am, Thursday, 08'th Apr 2021
SAN DIEGO and TAICANG, China, April 08, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical
Deutsche Bank Appointed as Depositary Bank for the Sponsored American Depositary Receipt Program of Connect Biopharma Holdings Limited
05:45pm, Thursday, 25'th Mar 2021
NEW YORK--(BUSINESS WIRE)--Deutsche Bank announced today its appointment as depositary bank for the Nasdaq-listed American Depositary Receipt program of Connect Biopharma Holdings Limited. Connect Bio
US IPO Weekly Recap: The IPO Market Heats Up In An 11 IPO Week
11:43am, Sunday, 21'st Mar 2021
The IPO market stayed busy this past week, with 11 IPOs raising $3.0 billion. New filers continued to fill the IPO pipeline, with 8 IPOs and 46 SPACs submitting initial filings.
Qiming's Portfolio Company Connect Biopharma Lists on Nasdaq
09:00pm, Friday, 19'th Mar 2021
SHANGHAI, March 19, 2021 /PRNewswire/ -- Qiming Venture Partners' portfolio company Connect Biopharma today listed on the Nasdaq with the stock code "CNTB". The issue price is US$ 17.00/ADS.
